Novavax hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden during a royal visit to Uppsala County
GAITHERSBURG, Md., September 24, 2021 Novavax, Inc. the company Uppsala, Sweden affiliate manufacturing on Thursday 23 September. The visit included a discussion on NVX-CoV2373, Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine candidate, and the company’s role in the fight against the global pandemic.
“We applaud the royal family for their exceptional leadership in supporting vaccination efforts to end the pandemic in both Sweden and globally, ”says Magnus Sävenhed, CEO, Novavax AB. . “
One of two Novavax-owned manufacturing companies, Novavax AB, produces the company’s patented saponin-based Matrix M adjuvant, a key component in several vaccine candidates that have been shown to improve the immune response and enable vaccine dose savings. It is currently being evaluated in vaccine candidates, including NVX-CoV2373, NanoFlu™, a recent announced investigative combination vaccine against COVID-NanoFlu and in clinical trials of several malaria vaccines.
NVX-CoV2373 is being evaluated in two crucial Phase 3 studies: a study in the UK showing 96.4% efficacy against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy in total; and the PREVENT-19 study in the United States and Mexico, which showed 100% protection against moderate and severe disease and 90.4% overall effectiveness. It was generally well tolerated and elicited a robust antibody response.
NVX-CoV2373 is a protein-based vaccine candidate constructed from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus nail protein (S) and is formulated with Novavax’s patented saponin-based Matrix M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate nor cause COVID-19.
Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen requires two doses of 0.5 ml (5 micrograms antigen and 50 micrograms Matrix-M adjuvant) given intramuscularly at 21 day intervals. The vaccine is stored at 2 ° – 8 ° Celsius, which enables the use of existing vaccine supplies and cold chain channels.
About NanoFlu ™
NanoFlu ™ is a quadrivalent recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced in Novavax SF9 insect cell baculovirus. NanoFlu uses HA amino acid protein sequences that are the same as the recommended circulating wild-type HA sequences and contains Novavax’s patented saponin-based Matrix-M adjuvant.
About Matrix-M ™ adjuvant
Novavax’s patented saponin-based Matrix M adjuvant has shown a potent and well-tolerated effect by stimulating antigen-presenting entry to the injection site and improving antigen presentation in local lymph nodes, which increases the immune response.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s own recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to meet urgent global health needs. Novavax is conducting late clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu ™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its crucial Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates contain Novavax proprietary saponin-based Matrix M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
Statements here about Novavax’s future, its operating plans and prospects, the ongoing development of NVX-CoV2373 and other candidates for Novavax vaccine products, the growth of Novavax AB and the role that Novavax can play in combating the COVID-19 pandemic are forward-looking statements. Novavax warns that these forward-looking statements are subject to many risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include challenges that, alone or together with partners, meet various safety, efficiency and product characterization requirements, including those related to process qualification and analysis validation, that are necessary to satisfy applicable regulators. difficulties in obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, for Novavax’s ability to follow planned regulatory paths; challenges to meet contractual requirements under agreements with several commercial, government and other entities; challenges to effectively manage our growth and increased complexity in our business; and the other risk factors identified in the section “Risk factors” and “Management’s discussion and analysis of financial condition and operating results” in Novavax’s annual report on form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q, filed with the Securities and Exchange Commission (SEC). We warn investors not to rely heavily on forward-looking statements in this press release. You are encouraged to read our applications to the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release apply only from the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to significant risks and uncertainties, including those mentioned above. Investors, potential investors and others should carefully consider these risks and uncertainties.
Erika Schultz | 240-268-2022
Alexandra Roy | 617-221-9197
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
View original content for downloading multimedia:https://www.prnewswire.com/news-releases/novavax-hosts-hm-king-carl-xvi-gustaf-and-hm-queen-silvia-of-sweden-during-royal-visit-to-uppsala- län-301384735.html
SOURCE Novavax, Inc.